Q-omics provides the consensus-scored RPS3AP46 profile across patient tissues and cancer cell-line models. RPS3AP46 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, RPS3AP46 is differentially expressed in 10, with the highest sampling consensus in COAD. Additionally, RPS3AP46 RNA expression shows 10,323 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight LUAD, COAD, and HNSC as cancer lineages where RPS3AP46 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPS3AP46 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPS3AP46 survival associations across molecular data types. RPS3AP46 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPS3AP46 RNA expression–survival associations across cancer types. High RPS3AP46 expression shows unfavorable associations in LUAD, UCS, ACC and KICH, but favorable associations in KIRP and LAML. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify LUAD as the clearest survival context for RPS3AP46 RNA expression.
This table summarizes RPS3AP46 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for RPS3AP46. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPS3AP46 shows higher tumor expression in COAD, KIRP, READ, LIHC, CHOL and UCEC. The COAD box plot shows higher RPS3AP46 RNA expression in tumor versus normal tissue (log2 FC = +0.569, t-test p < 0.001).
This table shows molecular features associated with RPS3AP46 in patient tissues and cancer cell lines. In patient samples, RPS3AP46 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set.
